148 related articles for article (PubMed ID: 18805575)
1. Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery.
Palma L; Marcus V; Gilbert L; Chong G; Foulkes WD
Gynecol Oncol; 2008 Dec; 111(3):575-8. PubMed ID: 18805575
[TBL] [Abstract][Full Text] [Related]
2. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
[TBL] [Abstract][Full Text] [Related]
3. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
[TBL] [Abstract][Full Text] [Related]
4. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
6. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
7. [Synchronous primary endometrial and fallopian tube cancers: one case report].
Wang H; Xiao SS; Zeng F
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2093-4. PubMed ID: 22200722
[TBL] [Abstract][Full Text] [Related]
8. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
9. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation.
Stuckless S; Green J; Dawson L; Barrett B; Woods MO; Dicks E; Parfrey PS
Clin Genet; 2013 Apr; 83(4):359-64. PubMed ID: 22775459
[TBL] [Abstract][Full Text] [Related]
10. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
[TBL] [Abstract][Full Text] [Related]
11. Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Brown JV; Epstein HD; Mattison JN; Micha JP; Rettenmaier MA; Goldstein BH
J Minim Invasive Gynecol; 2008; 15(6):749-51. PubMed ID: 18971141
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter flow cytometry in the diagnosis of a gynaecologic double tumor: a case report.
Mertens HJ; Nap M; Leers MP; Salemans TH
Virchows Arch; 2003 Mar; 442(3):294-7. PubMed ID: 12647221
[TBL] [Abstract][Full Text] [Related]
13. [A rare case of an adenomatoid mesothelioma of the fallopian tube combined with ovarian stromal hyperplasia and hyperthecosis, endometrial adenocarcinoma and endometriosis interna].
Nikolaeva M; Vasileva Z; Gorchev G
Akush Ginekol (Sofiia); 1997; 36(3):54-5. PubMed ID: 9618964
[TBL] [Abstract][Full Text] [Related]
14. Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
Saglam A; Bozdag G; Kuzey GM; Kuçukali T; Ayhan A
Arch Gynecol Obstet; 2008 Jun; 277(6):557-62. PubMed ID: 18066567
[TBL] [Abstract][Full Text] [Related]
15. Synchronous lung tumours in a patient with metachronous colorectal carcinoma and a germline MSH2 mutation.
Canney A; Sheahan K; Keegan D; Tolan M; Hyland J; Green A
J Clin Pathol; 2009 May; 62(5):471-3. PubMed ID: 19398597
[TBL] [Abstract][Full Text] [Related]
16. Three synchronous primary pelvic cancers--a case report.
Căpîlna ME; Rusu SC; Szabo B; Marian C
Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):107-10. PubMed ID: 24741785
[TBL] [Abstract][Full Text] [Related]
17. Multiple synchronous primary gynecologic malignancies in an MSH2 mutation carrier with endometriosis.
Shoni M; Parra-Herran CE; May T; Wright AA; Feltmate CM
J Clin Oncol; 2013 Jan; 31(3):e33-6. PubMed ID: 23213089
[No Abstract] [Full Text] [Related]
18. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
19. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
20. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
